Search Results

Company has prevailed in 16 of 17 ovarian cases tried in the last 11 years Company will reverse approximately $7 billion from amounts previously reserved for the bankruptcy resolution

SmartfIRE 12-month data demonstrated 86.9% effectiveness when utilized with high adherence to the recommended ablation workflow and significant quality of life improvements using the Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter1 Additional real-world evidence from company-funded REAL AF registry shows equivalent outcomes with zero or reduced fluoroscopy versus conventional approaches

The company’s commitment to developing solutions that tackle the world’s most pressing health challenges has helped Johnson & Johnson be recognized as the top-ranked healthcare company on the list.

Impella heart pump upgraded to Class 2a in ACC/AHA treatment guideline for cardiogenic shock secondary to STEMI

Median overall survival not yet reached with projected improvement of more than one year versus osimertinib

Oral presentation features new data from the 24-week pivotal Vivacity-MG3 study which show sustained disease control through treatment with nipocalimab on the clinician-assessed QMGa score in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+ Nipocalimab data demonstrate longer-term sustained disease control as measured by MG-ADLb and QMG scores from the ongoing open-label extension (OLE) of the Vivacity-MG3 study Johnson & Johnson filed a Biologics License Application (BLA) for nipocalimab in August 2024 and was granted U.S. FDA Priority Review for the treatment of gMG Real-world studies highlight the unmet need of patients living with gMG, including those who are pregnant or receiving steroids

With just an internet connection, health workers anywhere can access more than 50 high-quality training courses—from basic surgical techniques to advanced procedures.